Verily and Google have developed a machine learning algorithm that can automatically detect diabetes-related eye disease, which could be used to take pressure off services in countries wher
UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP).
US ophthalmology technology firm EyeQue has launched VisionCheck, which it says is the world’s first automated optical device allowing consumers to measure and track their refractive error
Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.
Novartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract surgery for surgeons and patients.